U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07436455) titled 'F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer' on Feb. 15.
Brief Summary: In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity.
F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-io...